vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $26.2M, roughly 1.5× BCB BANCORP INC). BCB BANCORP INC runs the higher net margin — -49.7% vs -161.8%, a 112.1% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 13.1%). BCB BANCORP INC produced more free cash flow last quarter ($34.9M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
BCBP vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $38.3M |
| Net Profit | $-12.0M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | -71.9% | -169.0% |
| Net Margin | -49.7% | -161.8% |
| Revenue YoY | 13.1% | 407.0% |
| Net Profit YoY | -467.6% | -4.7% |
| EPS (diluted) | $-0.73 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $38.3M | ||
| Q3 25 | $26.5M | $32.1M | ||
| Q2 25 | $25.2M | $26.4M | ||
| Q1 25 | $23.8M | $16.5M | ||
| Q4 24 | $23.1M | $7.6M | ||
| Q3 24 | $26.2M | $6.1M | ||
| Q2 24 | $20.4M | — | ||
| Q1 24 | $25.3M | — |
| Q4 25 | $-12.0M | $-61.9M | ||
| Q3 25 | $4.3M | $-67.3M | ||
| Q2 25 | $3.6M | $-92.6M | ||
| Q1 25 | $-8.3M | $-129.6M | ||
| Q4 24 | $3.3M | $-59.2M | ||
| Q3 24 | $6.7M | $-85.7M | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -71.9% | -169.0% | ||
| Q3 25 | 21.9% | -173.5% | ||
| Q2 25 | 19.9% | -269.8% | ||
| Q1 25 | -49.2% | -390.1% | ||
| Q4 24 | 19.9% | -919.0% | ||
| Q3 24 | 35.7% | -1314.3% | ||
| Q2 24 | 19.5% | — | ||
| Q1 24 | 33.0% | — |
| Q4 25 | -49.7% | -161.8% | ||
| Q3 25 | 16.1% | -209.8% | ||
| Q2 25 | 14.2% | -350.3% | ||
| Q1 25 | -35.0% | -784.9% | ||
| Q4 24 | 14.1% | -783.4% | ||
| Q3 24 | 25.5% | -1404.0% | ||
| Q2 24 | 13.8% | — | ||
| Q1 24 | 23.2% | — |
| Q4 25 | $-0.73 | $-0.06 | ||
| Q3 25 | $0.22 | $-0.07 | ||
| Q2 25 | $0.18 | $-0.10 | ||
| Q1 25 | $-0.51 | $-0.15 | ||
| Q4 24 | $0.17 | $-0.08 | ||
| Q3 24 | $0.36 | $-0.14 | ||
| Q2 24 | $0.14 | — | ||
| Q1 24 | $0.32 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $-500.5M |
| Total Assets | $3.3B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $242.8M | ||
| Q3 25 | — | $257.8M | ||
| Q2 25 | — | $153.7M | ||
| Q1 25 | — | $61.6M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $130.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $304.3M | $-500.5M | ||
| Q3 25 | $318.5M | $-524.3M | ||
| Q2 25 | $315.7M | $-570.7M | ||
| Q1 25 | $314.7M | $-591.4M | ||
| Q4 24 | $323.9M | $-489.1M | ||
| Q3 24 | $328.1M | $-745.1M | ||
| Q2 24 | $320.7M | — | ||
| Q1 24 | $320.1M | — |
| Q4 25 | $3.3B | $501.9M | ||
| Q3 25 | $3.4B | $519.0M | ||
| Q2 25 | $3.4B | $402.1M | ||
| Q1 25 | $3.5B | $303.8M | ||
| Q4 24 | $3.6B | $382.9M | ||
| Q3 24 | $3.6B | $364.6M | ||
| Q2 24 | $3.8B | — | ||
| Q1 24 | $3.8B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-70.4M |
| Free Cash FlowOCF − Capex | $34.9M | $-71.3M |
| FCF MarginFCF / Revenue | 133.3% | -186.2% |
| Capex IntensityCapex / Revenue | 4.0% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $-70.4M | ||
| Q3 25 | $8.7M | $-68.9M | ||
| Q2 25 | $10.3M | $-79.7M | ||
| Q1 25 | $5.0M | $-85.9M | ||
| Q4 24 | $67.7M | $-85.1M | ||
| Q3 24 | $43.5M | $-98.8M | ||
| Q2 24 | $8.1M | — | ||
| Q1 24 | $8.3M | — |
| Q4 25 | $34.9M | $-71.3M | ||
| Q3 25 | $8.5M | $-69.6M | ||
| Q2 25 | $10.2M | $-80.8M | ||
| Q1 25 | $4.7M | $-87.0M | ||
| Q4 24 | $66.5M | $-87.3M | ||
| Q3 24 | $43.4M | $-101.6M | ||
| Q2 24 | $8.1M | — | ||
| Q1 24 | $8.1M | — |
| Q4 25 | 133.3% | -186.2% | ||
| Q3 25 | 32.0% | -217.2% | ||
| Q2 25 | 40.4% | -305.9% | ||
| Q1 25 | 19.8% | -526.9% | ||
| Q4 24 | 287.5% | -1155.4% | ||
| Q3 24 | 166.0% | -1663.2% | ||
| Q2 24 | 39.6% | — | ||
| Q1 24 | 32.3% | — |
| Q4 25 | 4.0% | 2.4% | ||
| Q3 25 | 1.1% | 2.3% | ||
| Q2 25 | 0.6% | 4.1% | ||
| Q1 25 | 1.2% | 6.8% | ||
| Q4 24 | 5.3% | 28.0% | ||
| Q3 24 | 0.3% | 45.7% | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
